Variables | Training cohort (n = 170) | Validation cohort (n = 155) | ||||
---|---|---|---|---|---|---|
SIRI | p | SIRI | p | |||
≤ 1.12 | > 1.12 | ≤ 1.12 | > 1.12 | |||
Gender, No.(%) | 0.620 | 0.038 | ||||
male | 81 (64.8) | 31 (68.9) | 78 (70.9) | 39 (86.7) | ||
female | 44 (35.2) | 14 (31.3) | 32 (29.1) | 6 (13.3) | ||
Age, No.(%) | 0.293 | 0.520 | ||||
≤ 55 | 101 (80.8) | 33 (73.3) | 88 (80.0) | 38 (84.4) | ||
> 55 | 24 (19.2) | 12 (26.7) | 22 (20.0) | 7 (15.6) | ||
Smoke | 0.974 | 0.037 | ||||
no | 83 (66.4) | 30 (66.7) | 69 (62.7) | 20 (44.4) | ||
yes | 42 (33.6) | 15 (33.3) | 41 (37.3) | 25 (55.6) | ||
AJCC stage (8th), No.(%) | 0.037 | 0.059 | ||||
I-II | 43 (34.4) | 8 (17.8) | 39 (35.5) | 9 (20.0) | ||
III-IVb | 82 (65.6) | 37 (82.2) | 71 (64.5) | 36 (80.0) | ||
Tumor classification, No.(%) | 0.010 | 0.622 | ||||
T1-T2 | 61 (48.8) | 12 (26.7) | 61 (55.5) | 23 (51.1) | ||
T3-T4 | 64 (51.2) | 33 (73.3) | 49 (44.5) | 22 (48.9) | ||
Node classification, No.(%) | 0.113 | 0.081 | ||||
N0-N1 | 70 (56.0) | 19 (42.2) | 61 (55.5) | 18 (40.0) | ||
N2-N3 | 55 (44.0) | 26 (57.8) | 49 (44.5) | 27 (60.0) | ||
Metastasis, No.(%) | 0.656 | 0.498 | ||||
Non-metastasis | 121 (96.8) | 43 (95.6) | 109 (99.1) | 44 (97.8) | ||
Metastasis | 4 (3.2) | 2 (4.4) | 1 (0.9) | 1 (2.2) |